Understanding the Genetic Architecture of Parkinson's Disease

The Global Parkinson’s Genetics Program (GP2) is an ambitious five-year program to genotype >150,000 volunteers around the world to further understand the genetic architecture of Parkinson’s disease (PD). There is still much to learn about genetic risk factors and the path to further understanding requires working collaboratively and openly sharing data, processes, and results.

Submit a Cohort

Collaborate with us and submit a cohort to GP2. Fill out our form to get started.

GP2 Updates

Check out the latest news about GP2.

  • GP2 Opportunities

    By GP2 on

    Development is an important component of our program; our focus is to provide training and other funding opportunities for the next generation of Parkinson’s disease researchers around the world. GP2 will offer these opportunities to the entire neurodegeneration community through the course of the program.

  • Introduction to GP2

    By Andrew Singleton on

    In the first GP2 blog post, Andrew Singleton, NIH Distinguished Investigator and GP2 Lead, introduces the program's aims, values and vision.

  • Introducing the GP2 Learning Platform

    By GP2 on

    Training is central to the GP2 effort. Visit our learning platform for training on topics related to Parkinson’s disease genetics.

Latest Blog Posts

Read the latest blogs from GP2’s scientists and collaborators.

  • Decoding the Aliens Within

    GP2 aims to identify novel disease-causing genes and mutations. Benjamin Stecher outlines his hopes for GP2, as we delve into the unknown and build a foundation of knowledge from which new therapies may come.

  • Open Science Opens Doors

    By Bradford Casey | GP2 Values

    In GP2, underlying data, analytical processes, and results will be made available to the research community as quickly as possible, with minimal barriers to access and use. The latest blog post by Bradford Casey highlights the value and importance of open science.

  • A letter to the patient community from Randy Schekman, ASAP Scientific Director

    By Randy Schekman and Benjamin Stecher | GP2 Values

    ASAP Scientific Director, Randy Schekman, expresses his personal and professional connection with Parkinson's disease in a letter to the patient community, shared by patient advocate Benjamin Stecher.

Working Groups

Find out about GP2’s working groups and their recently accomplished milestones.